Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 77 out of 100. Brain scans and imaging

Topic: Amyloid, tau and blood-test diagnosis

We found a sequence to pathological changes, with rates of Aβ deposition in mutation carriers being significantly different from those in non-carriers first (across regions that showed a significant difference, at a mean of 18·9 years [SD 3·3] before expected onset), followed by hypometabolism (14·1 years [5·1] before expected onset), and lastly structural decline (4·7 years [4·2] before expected onset). Interpretation Mutation carriers had elevations in Aβ deposition, reduced glucose metabolism, and cortical thinning compared with non-carriers which preceded the expected onset of dementia.

Key findings

Why it matters

In people from families with inherited (autosomal dominant) Alzheimer's disease, brain scans of mutation carriers began to differ from those of non-carrier relatives in a set order: amyloid deposition first (on average 18.9 years before expected onset), then reduced glucose metabolism (14.1 years), then structural decline (4.7 years). These figures are averages across brain regions of when the differences became statistically detectable, not personal timelines, and they varied by several years. The study shows these changes come before the expected start of dementia in this inherited form; it does not show that one change causes the next, or that the same timing applies to late-life Alzheimer's.

Study details

How this study scored 77/100
How this study's score is builtJournal tier 9 of 10; Journal's citation record 3 of 4; Study design 7 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 2 of 5; Sample size 2 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomised / blinded 0 of 2; Times cited 6 of 7; Citations per year 5 of 5; Impact for its field and year 6 of 6; Cited by studies here 4 of 6; Still being cited 4 of 4; Senior author's track record 3 of 4; Institution's track record 3 of 3; Multi-centre collaboration 3 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 77 of 100.77 of 100 points earned23 not earned

Published in a leading specialty journal, and it is a longitudinal study following the same people over time. Scored zero for effect reported and randomised / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 9 / 10 Tier 2 — leading specialty journal (The Lancet. Neurology)
Journal's citation record 3 / 4 The Lancet Neurology: journal h-index 457 (OpenAlex, 2026-10-29)
Study design 7 / 12 A longitudinal study following the same people over time
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 2 / 5 2018 — within 10 year(s) of the newest study here
Sample size 2 / 4 346 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomised / blinded 0 / 2 No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 6 / 7 Cited 606 times (OpenAlex, 2026-10-10)
Citations per year 5 / 5 60.6 citations a year over 10 year(s) since 2018
Impact for its field and year 6 / 6 Cited 41.0× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 4 / 6 Cited by 62 other studies in this library
Still being cited 4 / 4 Cited 206 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 3 / 4 Last-listed author Tammie L.S. Benzinger: h-index 98 (OpenAlex, whole career)
Institution's track record 3 / 3 Harvard University: institution h-index 3,235 (OpenAlex)
Multi-centre collaboration 3 / 3 OpenAlex lists 24 institution(s) in 4 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 29397305)
Free to read 2 / 2 Free to read
Total 77 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

APA 7th

Gordon, B. A., Blazey, T. M., Su, Y., Hari-Raj, A., Dincer, A., Flores, S., et al. (2018). Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study. The Lancet. Neurology. https://doi.org/10.1016/s1474-4422(18)30028-0

Vancouver

Gordon BA, Blazey TM, Su Y, Hari-Raj A, Dincer A, Flores S, et al. Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study. The Lancet. Neurology. 2018. doi:10.1016/s1474-4422(18)30028-0. PMID: 29397305.

BibTeX

@article{gordon2018-29397305,
  author  = {Gordon, B. A. and Blazey, T. M. and Su, Y. and Hari-Raj, A. and Dincer, A. and Flores, S. and Christensen, J. and McDade, E. and others},
  title   = {{Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study}},
  journal = {The Lancet. Neurology},
  year    = {2018},
  doi     = {10.1016/s1474-4422(18)30028-0},
  pmid    = {29397305},
  url     = {https://doi.org/10.1016/s1474-4422(18)30028-0}
}

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 14.

Later studies that cite this one

62 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.

Related studies in Brain scans and imaging

Also tagged “classification”

835 studies in the library carry the topic tag “classification”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 835 tagged studies.

Similar studies

More on Brain scans and imaging

See all studies in Brain scans and imaging →